摘要
目的观察吉非替尼耐药肺腺癌H1975细胞在肺岩宁方、吉非替尼作用下体外增殖情况,探讨肺岩宁方逆转吉非替尼耐药可能的机制。方法选取肺腺癌T790M突变耐药株H1975细胞,分为对照组、吉非替尼组、肺岩宁方组和联合干预组。CCK-8法检测各组细胞在不同时间点(0 h、24 h、48 h、72 h)的增殖率;Western blot检测EGFR-PI3K/Akt/mTOR信号通路相关蛋白表达的影响。结果CCK-8结果显示,肺岩宁方组对于H1975细胞在体外增殖呈剂量依赖性抑制,即随着药物浓度的提高而增加;联合干预组对于抑制细胞体外增殖效果较单药明显。Western blot显示,联合干预组可下调p-EGFR、p-Akt、pmTOR的表达。结论肺岩宁方联合吉非替尼可抑制H1975细胞的体外增殖,体外抑制效果较单药治疗明显;其延缓吉非替尼耐药机制可能与下调EGFR-PI3K/Akt/mTOR信号通路相关蛋白的表达有关。
Objective To observe the proliferation of lung adenocarcinoma H1975 cells resistant to gefitinib in vitro under the action of Feiyanning Prescription(FYN)and gefitinib,and to explore the possible mechanism of FYN in reversing gefitinib resistance.Methods Lung adenocarcinoma T790M mutation-resistant strain H1975 cells were selected and divided into control group,gefitinib group,FYN group and combination group.CCK-8 assay was used to detect the proliferation rate of cells in each group at different time(0 h,24 h,48 h,and 72 h);Western blot was used to detect the expression of proteins related to EGFR-PI3K/Akt/mTOR signal pathway.Results The results of CCK-8 showed that FYN inhibited the proliferation of H1975 cells in vitro in a dose-dependent manner,that is,its inhibitory power increased with the increase of drug concentration,and the effect of combination drug on inhibiting cell proliferation in vitro was more obvious than that of single drug.Western blot showed that FYN combined with gefitinib could down-regulate the expression of p-EGFR,p-Akt and p-mTOR.Conclusion FYN combined with gefitinib can inhibit the proliferation of H1975 cells in vitro,and the inhibitory effect in vitro is more significant than that of gefitinib.The mechanism of delaying gefitinib resistance may be related to the down-regulation of EGFR-PI3K/Akt/mTOR signal pathway related protein expression.
作者
方旭鹏
方丹
邓海滨
徐振晔
王中奇
苏婉
马玥
王立芳
FANG Xupeng;FANG Dan;DENG Haibin;XU Zhenye;WANG Zhongqi;SU Wan;MA Yue;WANG Lifang(The Second Department of Oncology,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China)
出处
《上海中医药杂志》
2022年第8期79-83,共5页
Shanghai Journal of Traditional Chinese Medicine
基金
国家自然科学基金项目(81603546)
上海市教委科研创新计划重大项目(2017-01-07-00-10-E00064)
上海申康医院发展中心市级医院新兴前沿技术联合攻关项目(SHDC1202123)
关键词
肺腺癌
肺岩宁方
吉非替尼
H1975细胞
体外增殖
中药研究
lung adenocarcinoma
Feiyanning Prescription
gefitinib
H1975 cells
proliferation in vitro
traditional Chinese herbal medicine research
作者简介
方旭鹏,男,硕士研究生,主要从事中医药防治恶性肿瘤的基础及临床研究工作;共同第一作者:方丹;通信作者:王立芳,主任医师,硕士研究生导师,E-mail:13816927507@139.com
